RxDoctor Payments Data

Hoda Rahmani, MD

Family Medicine · Elkhart, INNPI 1063975332

Payments from drug & device makers

$1,095in general payments, 2019–2025

Across 46 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$211
  • Novo Nordisk$139
  • Pfizer$125
  • Procept Biorobotics Corporation$119
  • AbbVie$107
  • Astellas Pharma US Inc$92
  • plus $302 from 8 others

What the payments were for

  • Food & beverage$1,095100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,095 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$30,104
Medicare patients
128
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$44,799
OzempicSemaglutide27$25,836
FarxigaDapagliflozin Propanediol19$24,406
EliquisApixaban22$16,876
XareltoRivaroxaban12$14,194
TrulicityDulaglutide13$11,653
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$8,779
Breo ElliptaFluticasone/Vilanterol12$6,944
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$3,231
Mometasone Furoate38$3,125
Albuterol Sulfate HfaAlbuterol Sulfate107$2,989
SynthroidLevothyroxine Sodium26$1,783
Atorvastatin Calcium134$1,542
Omeprazole139$1,511
Metoprolol Succinate65$1,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$44,79935 claims
AstraZenecaFarxiga, Breztri Aerosphere$211$33,18534 claims
Novo NordiskOzempic$139$25,83627 claims
PfizerEliquis$125$16,87622 claims
Johnson & JohnsonXarelto$35$14,19412 claims
Lilly USA, LLCTrulicity$70$11,65313 claims
GSKBreo Ellipta$37$6,94412 claims
AbbVieSynthroid$107$1,78326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →